GlassScriptPhysician profile
Shaun J Cardozo
NPI 1952638272
$3,066.20
in general payments reported to CMS, 2019-2025
26 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $226 · 2021: $538 · 2022: $237 · 2023: $490 · 2024: $271 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $540.34 | 2023-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $328.01 | 2020-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $279.69 | 2021-2025 | Verquvo |
| Amgen INC. | $262.09 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $253.83 | 2019-2024 | |
| Boston Scientific Corporation | $159.44 | 2023-2025 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Kestra Medical Technology Services, INC. | $156.58 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $132.32 | 2019-2025 | Camzyos |
| Angiodynamics, INC. | $127.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $115.60 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $102.47 | 2020-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.48 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $100.37 | 2019-2021 | |
| Abbott Laboratories | $66.80 | 2025 | Aveir |
| Astrazeneca Pharmaceuticals LP | $66.13 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39.57 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $35.82 | 2025 | Rezdiffra |
| Philips North America LLC | $32.06 | 2024 | (5044) Mcot, (Ck4) Mcot |
| Kiniksa Pharmaceuticals International, Plc | $28.72 | 2024 | Arcalyst |
| Apellis Pharmaceuticals, INC. | $27.86 | 2025 | Empaveli |
| Actelion Pharmaceuticals US, INC. | $25.25 | 2025 | Uptravi, Opsumit |
| Lilly USA, LLC | $23.87 | 2020 | |
| Exact Sciences Corporation | $19.27 | 2025 | Cologuard Collection Kit |
| Akcea Therapeutics, INC. | $17.62 | 2020 | |
| Edwards Lifesciences Corporation | $13.59 | 2019 | |
| Ekos Corporation | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Cardozo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.